Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ketamine ease severe BPD symptoms? new pilot study aims to find out

NCT ID NCT07099534

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study will test whether two intravenous infusions of ketamine, given 24 hours apart, can quickly reduce symptoms in 38 adults with severe borderline personality disorder (BPD). Participants also receive standard psychiatric care. The main goal is to see if symptoms improve by day 9, with follow-ups up to 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine
What this could lead to
If it works, this could point toward a rapid-acting treatment option for severe BPD symptoms.
What could go wrong
This is a very small pilot study (38 people) with no placebo group, so results may not be reliable or generalizable. Ketamine can cause side effects like dissociation and nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 38 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged 18 to 65 years * Fluent in French * Person affiliated with or receiving social security benefits. * Diagnosis of borderline personality disorder established according to the DSM-5 MINI criteria (5 out of 9 criteria) * Severe borderline personality disorder * Patient receiving stable pharmacological (antipsychotic, mood stabilizer, antidepressant) and/or non-pharmacological (schema therapy, DBT) treatment for four weeks Exclusion Criteria: * Personal history of an acute psychotic episode or chronic psychotic disorder * Personal history of a manic or hypomanic episode * Family history (first-degree relatives) of a psychotic disorder * Current severe depressive episode * Recreational ketamine use (multi-weekly ketamine use) * New long-term treatment introduced within the previous four weeks (antidepressant, antipsychotic, mood stabilizer) * Prescription of an Monoamine oxidase inhibitors (increased risk of hypertension) * Specific absolute contraindication to ketamine * History of cirrhosis or major liver function test abnormalities * Major ECG abnormality

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline personality disorder (BPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline personality disorder (BPD) Infusion of ketamine in severe borderline personality disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.